Who is sponsoring NCT05021588?

NCT05021588 is sponsored by Assiut University.

What drugs are being tested in NCT05021588?

Interventions in NCT05021588: steroid and anticoagulants according to different protocols..

What condition does NCT05021588 study?

NCT05021588 studies Pneumonia, Viral.

Is NCT05021588 still recruiting?

NCT05021588 is currently completed. Last updated 25 August 2021.

Last reviewed 2021-08-25 · How we verify

NCT05021588: SARS-CoV-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Steroid and Anticoagulant Therapy in covid19

Completed NA Last updated 25 August 2021

What this trial tests

NA trial testing steroid and anticoagulants according to different protocols. in Pneumonia, Viral in 123 participants. Completed in 10 September 2020.

Timeline

12 April 2020

Primary endpoint
2 August 2020

10 September 2020

Quick facts

Lead sponsor	Assiut University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	123
Start date	12 April 2020
Primary completion	2 August 2020
Estimated completion	10 September 2020
Sites	1 location across Egypt

Drugs / interventions tested

steroid and anticoagulants according to different protocols.

Conditions studied

Pneumonia, Viral — all drugs for Pneumonia, Viral →

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Pneumonia, Viral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As COVID-19 has neither standard treatment protocol nor guidelines, there are many treatment protocols foranti-inflammatory corticosteroids and anti-coagulations for severe COVID-19 pneumonia patients. This study aimed to assess the most suitable modality in this high-risk group. Methods: A prospective, experimental study design was adopted, that included 123 severe COVID-19 pneumonia patientsadmitted at Assiut UniversityHospital from April 10th, 2020, to September10th, 2020. Patients were divided into 3 groups according to a combined corticosteroid and anticoagulants therapy protocols. Group A included 32 patients, group B included 45 patients, and group C included 46 patients. Assessment of cases was conducted according to the treatment type and duration, weaning duration from oxygen therapy, length of hospital and ICU stay, and complications during treatment.Three months follow up after discharge was performed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Challenges in Steroid and Anticoagulant Therapy in Severe COVID-19 Pneumonia: A Prospective Study.
Hassan AT, Elmoniem AEA, Abdelrady MM, Mohamed ME, et al · · 2021 · cited 5× · PMID 34680795 · DOI 10.3390/antibiotics10101214

Verify or expand the search:

Other recruiting trials for Pneumonia, Viral

Currently open trials in the same condition.

NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05021588 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 25 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05021588.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing